By Nono Hu, Senior Manager, Branding & Messaging, LSN
Yesterday, the sixth Redefining Early Stage Investments (RESI) Conference was held at the Westin Copley Place, Boston. Featuring approximately 200 investors, 250 biotech, medtech and healthcare IT entrepreneurs, and 130 service providers, this event is the biggest RESI ever.
In the exhibit hall, 30 of the most innovative early stage life science companies at the event were chosen to participate in a virtual investment contest – The RESI Innovation Challenge, showcasing cutting-edge life science technologies in poster displays and competing to raise the most RESI Cash. Without further ado here are the top 3 contestants!
First Prize Winner: Rna Diagnostics
Rna Diagnostics is commercializing the RNA Disruption Assay (RDA™) to address the serious problem of over-treatment of cancers with ineffective chemotherapy. RDA accurately assesses effectiveness of chemotherapy in real-time. Chemotherapy effect is assessed as early as 14 days after therapy initiation by quantifying tumour RNA disruption. High RNA disruption is strongly correlated with pathological complete response and enhanced long term disease free survival. RDA assesses treatment efficacy of conventional and targeted cancer drugs in breast cancer. RDA is delivered as a lab developed test service. No FDA approval required. Collaborations and prospective trials of RDA in multiple cancers are underway / planned in North America, Europe & Asia. RDA provides patients with improved outcomes while reducing cost for healthcare payers.
As a first prize winner, Rna Diagnostics will receive complimentary subscription to the LSN Investor Platform.
Second Prize Winner: KIYATEC
KIYATEC prioritizes accurate ex vivo prediction of patients’ drug response, focused primarily on data correlation to human clinical outcomes. Our drug response profiling services utilize phenotypic 3D cell-based models for predicting patient response. KIYATEC’s 3D perfusion tissue microenvironments are particularly useful for investigating efficacy and modeling resistance of cancer therapeutics.
As a second prize winner, KIYATEC will receive two complimentary RESI tickets.
Third Prize Winner: Synthonics
Metal coordination, or attaching a metal to an active agent to control its absorption and release, represents a significant advance in drug delivery and development. It is a powerful, flexible and elegant means to create a new generation of safer and more effective patent protected drugs (“MCPs”). In addition to imparting a range of desired characteristics, metal coordination enjoys significant regulatory advantages. MCPs of approved drugs are eligible for approval under section 505(b)(2), which allows for faster and less expensive drug development. Moreover, they are patentable as new compositions of matter even if the parent molecule is well known. Synthonics intends to begin human trials in 2016 on its controlled release formulations of levodopa for Parkinson’s disease and liothyronine (T3) for hypothyroidism.
As a third prize winner, Synthonics will receive one complimentary RESI ticket.
Congratulations! We hope to see you at RESI San Francisco on January 12, 2016.